CD44v3 and CD44v6 isoforms on T cells are able to discriminate different disease activity degrees and phenotypes in systemic lupus erythematosus patients

Abstract

Background

Adhesion molecule CD44 contributes to T cell migration into target organs. A higher expression of CD44v3 and v6 isoforms has been identified on T cells from systemic lupus erythematosus (SLE) patients. The aim of this study was to investigate the expression of CD44v3/v6 on T cells of SLE patients in order to evaluate their correlation with clinical features.

Methods

Sixteen healthy subjects (HSs) and 33 SLE female patients were enrolled. Fifteen patients were in remission (Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) = 0) and 18 patients had an active disease (SLEDAI-2K ≥ 4). Experiments were conducted by flow cytometry.

Results

Expression of CD44v3 on CD4⁺ and CD8⁺ T cells was higher in active patients compared to HSs (p = 0.0097 and p = 0.0096). CD44v3 on CD8⁺ T cells was also higher in active patients compared to patients in remission (p = 0.038). CD44v6 was higher on CD4⁺ and CD8⁺ T cells from active patients compared to HSs (p = 0.003 and p = 0.0036) and to patients in remission (p = 0.01 and p = 0.02). In active patients the ratio CD44v3/v6 was unbalanced towards isoform v6 on both T cell populations. In a receiver operating characteristic curve analysis, CD44v6 on CD4⁺ T cells was the most sensitive and specific one (specificity of 81.8%, sensitivity of 75%). Expression of CD44v6 on CD4⁺ and CD8⁺ T cells correlated with the SLEDAI-2K (p = 0.03, r = 0.38 and p = 0.02, r = 0.39). CD44v6 and CD44v3 on CD8⁺ T cells associated with nephritis and arthritis (p = 0.047 and p = 0.023).

Conclusions

CD44v3/v6 can be used as biomarkers of disease activity and phenotypes; isoform v6 on CD4⁺ T cells can be useful as a diagnostic biomarker.

Keywords

CD44v3/v6 systemic lupus erythematosus biomarkers disease activity arthritis nephritis

Get full access to this article

View all access options for this article.

References

Tsokos

. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110–2121.

Conti

Spinelli

Alessandri

et al.

Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response. Arterioscler Thromb Vasc Biol 2014; 34: 661–668.

Estess

DeGrendele

Pascual

Siegelman

. Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity. J Clin Invest 1998; 102: 1173–1182.

Suárez-Fueyo

Bradley

Tsokos

. T cells in systemic lupus erythematosus. Curr Opin Immunol 2016; 43: 32–38.

Tsokos

Costa Reis

Sullivan

. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 2016; 12: 716–730.

Gravano

Hoyer

. Promotion and prevention of autoimmune disease by CD8+ T cells. J Autoimmun 2013; 45: 68–79.

Sherman

Sleeman

Herrlich

Ponta

. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol 1994; 6: 726–733.

Screaton

Bell

Jackson

. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor: comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 1993; 268: 12235–12238.

Cohen

Bayliss

Crispin

et al.

T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis. Clin Immunol 2008; 128: 1–7.

10.

Seiter

Schadendorf

Tilgen

Zöller

. CD44 variant isoform expression in a variety of skin-associated autoimmune diseases. Clin Immunol Immunopathol 1998; 89: 79–93.

11.

Crispín

Keenan

Finnell

et al.

Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum 2010; 62: 1431–1437.

12.

van Vollenhoven

Mosca

Bertsias

et al.

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014; 73: 958–967.

13.

Ceccarelli

Perricone

Massaro

et al.

Assessment of disease activity in systemic lupus erythematosus: lights and shadows. Autoimmun Rev 2015; 14: 601–608.

14.

Ceccarelli

Perricone

Borgiani

et al.

Genetic factors in systemic lupus erythematosus: contribution to disease Phenotype. J Immunol Res 2015; 2015: 745647–745647.

15.

Lateef

Petri

. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 2012; 14(Suppl 4): S4–S4.

16.

Doria

Gatto

Zen

Iaccarino

Punzi

. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev 2014; 13: 770–777.

17.

Yee

Farewell

Isenberg

et al.

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) 2011; 50: 982–988.

18.

Blanco

Pitard

Viallard

Taupin

Pellegrin

Moreau

. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 201–211.

19.

Taher

Smit

Griffioen

Schilder-Tol

Borst

Pals

. Signaling through CD44 is mediated by tyrosine kinases. Association with p56lck in T lymphocytes. J Biol Chem 1996; 271: 2863–2867.

20.

Arch

Wirth

Hofmann

et al.

Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992; 257: 682–685.

21.

Naor

Nedvetzki

. CD44 in rheumatoid arthritis. Arthritis Res Ther 2003; 5: 105–115.

22.

Sela

Mauermann

Hershkoviz

et al.

The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-beta-mediated suppression of LFA-1 and CD44 expression and function. J Immunol 2005; 175: 7255–7263.

23.

Croft

Dall

Davies

Jackson

McIntyre

Kramer

. Complex CD44 splicing combinations in synovial fibroblasts from arthritic joints. Eur J Immunol 1997; 27: 1680–1684.

24.

Kelleher

Murphy

Hall

et al.

Expression of CD44 on rheumatoid synovial fluid lymphocytes. Ann Rheum Dis 1995; 54: 566–570.

25.

Mikecz

Brennan

Kim

Glant

. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nat Med 1995; 1: 558–563.

26.

Verdrengh

Holmdahl

Tarkowski

. Administration of antibodies to hyaluronan receptor (CD44) delays the start and ameliorates the severity of collagen II arthritis. Scand J Immunol 1995; 42: 353–358.

27.

Ceccarelli

Perricone

Cipriano

et al.

Joint involvement in systemic lupus erythematosus: from pathogenesis to clinical assessment. Semin Arthritis Rheum 2017; 47: 53–64.

28.

Ball

Bell

. Lupus arthritis: do we have a clinically useful classification? Rheumatology (Oxford) 2012; 51: 771–779.

29.

Amezcua-Guerra

Márquez-Velasco

Bojalil

. Erosive arthritis in systemic lupus erythematosus is associated with high serum C-reactive protein and anti-cyclic citrullinated peptide antibodies. Inflamm Res 2008; 57: 555–557.

30.

Zhu

Chen

et al.

CTLA-4 -1722T/C polymorphism and systemic lupus erythematosus susceptibility: a meta-analysis involving ten separate studies. Immunol Invest 2013; 42: 91–105.

31.

Ceccarelli

Massaro

Perricone

et al.

Jaccoud’s arthropathy in systemic lupus erythematosus: clinical, laboratory and ultrasonographic features. Clin Exp Rheumatol 2017; 35: 674–677.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.29 MB